MADISON, Wis., Nov. 9, 2018 /PRNewswire/ -- Exact Sciences
Corp. (Nasdaq: EXAS) today announced that company management will
be presenting at the following investor conference during November
and invited investors to participate by webcast.
- Jefferies 2018 London Healthcare Conference, London
Presentation and Q&A session on Thursday, Nov. 15 at 2:40
p.m. GMT, 9:40 a.m. EST
- Evercore ISI HealthconX, Boston
Fireside chat on Tuesday, Nov. 27 at
12:30 p.m. EST
About Exact Sciences Corp.
Exact Sciences Corp. is a molecular diagnostics company focused
on the early detection and prevention of the deadliest forms of
cancer. The company has exclusive intellectual property protecting
its non-invasive, molecular screening technology for the detection
of colorectal cancer. For more information, please visit the
company's website at www.exactsciences.com, follow Exact Sciences
on Twitter @ExactSciences or find Exact Sciences on Facebook.
Forward-Looking Statements
This news release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
that are intended to be covered by the "safe harbor" created by
those sections. Forward-looking statements, which are based on
certain assumptions and describe our future plans, strategies and
expectations, can generally be identified by the use of
forward-looking terms such as "believe," "expect," "may," "will,"
"should," "would," "could," "seek," "intend," "plan," "goal,"
"project," "estimate," "anticipate" or other comparable terms. All
statements other than statements of historical facts included in
this news release regarding our strategies, prospects, financial
condition, operations, costs, plans and objectives are
forward-looking statements. Examples of forward-looking statements
include, among others, statements we make regarding expected future
operating results, anticipated results of our sales and marketing
efforts, expectations concerning payer reimbursement and the
anticipated results of our product development efforts.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results and financial
condition may differ materially from those indicated in the
forward-looking statements. Therefore, you should not rely on any
of these forward-looking statements. Important factors that could
cause our actual results and financial condition to differ
materially from those indicated in the forward-looking statements
include, among others, the following: our ability to successfully
and profitably market our products and services; the acceptance of
our products and services by patients and healthcare providers; our
ability to meet demand for our products and services; the
willingness of health insurance companies and other payers to cover
our products and services and adequately reimburse us for such
products and services; the amount and nature of competition from
other cancer screening and diagnostic products and services; the
effects of the adoption, modification or repeal of any healthcare
reform law, rule, order, interpretation or policy; the effects of
changes in pricing, coverage and reimbursement for our products and
services, including without limitation as a result of the
Protecting Access to Medicare Act of 2014; recommendations,
guidelines and quality metrics issued by various organizations such
as the U.S. Preventive Services Task Force, the American Cancer
Society, and the National Committee for Quality Assurance regarding
cancer screening or our products and services; our ability to
successfully develop new products and services; our ability to
effectively utilize strategic partnerships and acquisitions; our
success establishing and maintaining collaborative, licensing and
supplier arrangements; our ability to maintain regulatory approvals
and comply with applicable regulations; and the other risks and
uncertainties described in the Risk Factors and in Management's
Discussion and Analysis of Financial Condition and Results of
Operations sections of our most recently filed Annual Report on
Form 10-K and our subsequently filed Quarterly Reports on Form
10-Q. We undertake no obligation to publicly update any
forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
Contact:
Megan
Jones
Exact Sciences Corp.
meganjones@exactsciences.com
608-535-8815
View original content to download
multimedia:http://www.prnewswire.com/news-releases/exact-sciences-to-participate-in-two-november-investor-conferences-300747113.html
SOURCE EXACT SCIENCES CORP